EGFR and glioblastoma: While clinical evidence is currently limited, experimental data using glioblastoma patient-derived cells have shown that the epidermal growth factor receptor (EGFR) kinase inhibitor erlotinib can deplete EGFR ecDNAs.21 Once the targeted drug loses its target, cancer cells become resistant.